How DHP Korea, a company specializing in eye drops, will be establishing a strategy to defend its sales ahead of the upcoming reimbursement reevaluations for its HA (hyaluronic acid) products next year is drawing attention.

In particular, this upcoming risk is highly likely to serve as a testbed to verify the company’s newly appointed CEO Eunyoung Park’s ability in crisis management and the creation of new growth engines. Eunyoung Park, who was formerly the SSK business unit head of Zuellig Pharma, was appointed head of DHP Korea last month.

One key point of concern is whether the Health Insurance Reimbursement and Assessment Service’s reimbursement reevaluations would result in partial r